- Generic name
- Levetiracetam
- Strength
- 250 mg
- Dosage form
- Tablet
- Manufactured by
- Naafco Pharma PLC.
Levista 250 Tablet
About Levista 250 Tablet
Made by Naafco Pharma PLC., Levista 250 is a tablet whose active ingredient is Levetiracetam. In other people, including children from one month of age, it may be added to other epilepsy medicines.
There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.
What is Levista 250 Tablet?
Levista 250 comes as a tablet with 250 mg of Levetiracetam, from Naafco Pharma PLC. Levista 250 is an extended-release tablet, meaning the medicine is released gradually after you swallow it. It belongs to a group of medicines known as adjunct anti-epileptic drugs, which are used alongside other treatments in the management of epilepsy. Do not stop or change this medicine on your own; ask your doctor or pharmacist if you have questions.
Uses of Levista 250
In other people, including children from one month of age, it may be added to other epilepsy medicines. It can be given alongside other anti-epileptic medicines in adults, adolescents, children and infants from one month of age. Only a doctor can confirm whether it fits a person's type of epilepsy. Your doctor will decide if it is suitable for you.
How to use Levista 250
Swallow the extended-release tablet whole with water, and do not crush or chew it unless your doctor or pharmacist says otherwise. Levista 250 is taken by mouth. The doctor decides the dose and how long the course should last, and may adjust it over time based on how you respond. Do not stop the medicine suddenly on your own, because the doctor needs to manage any change in treatment.
Side effects of Levista 250
In adults, the most common side effects include sleepiness, weakness, infection, and dizziness. Seek medical help promptly if you notice serious or unexpected symptoms, or if the person becomes very unwell. Tell your doctor if you experience any side effects that bother you or do not go away. Do not change your dose without speaking to your doctor first.
Safety and precautions
Levetiracetam is not recommended in pregnancy or in women who could become pregnant without using contraception, unless the doctor considers it clinically necessary. Before taking Levista 250, tell your doctor if you have kidney or liver problems, or a history of blood disorders. It passes into breast milk, so breastfeeding is generally not recommended; discuss this with the doctor. Tell your doctor about kidney or liver problems, because the dose may need adjusting.
Frequently asked questions
What does Levista 250 treat?
In other people, including children from one month of age, it may be added to other epilepsy medicines. It can be given alongside other anti-epileptic medicines in adults, adolescents, children and infants from one month of age.
How should I take Levista 250?
Swallow the extended-release tablet whole with water, and do not crush or chew it unless your doctor or pharmacist says otherwise. Levista 250 is taken by mouth.
What should I watch for while using Levista 250?
In adults, the most common side effects include sleepiness, weakness, infection, and dizziness. Seek medical help promptly if you notice serious or unexpected symptoms, or if the person becomes very unwell.
Is Levista 250 safe for everyone?
Levetiracetam is not recommended in pregnancy or in women who could become pregnant without using contraception, unless the doctor considers it clinically necessary. Before taking Levista 250, tell your doctor if you have kidney or liver problems, or a history of blood disorders.
Indications
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Dosage & Administration
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
Interaction
Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
Contraindications
Side Effects
- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Pregnancy & Lactation
Precautions & Warnings
Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
Overdose Effects
Storage Conditions
Alternative brands of Levetiracetam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.